ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,956.06
0.00%
US Tech 100
20,748.40
0.81%
다우존스 지수
43,433.12
0.00%
Bitcoin
86,071.14
2.38%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Stoke Therapeutics Inc (STOK) 시세

Stoke Therapeutics Inc

Stoke Therapeutics Inc (STOK)

NASDAQ
8.27
0.02
(0.24%)
마감 27 2월 6:00AM
15분 지연
8.27
0.00
( 0.00% )
시간외 단일가: 10:10PM
15분 지연

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

주요 통계 및 세부정보

가격
8.27
매수가
7.98
매도가
8.37
거래량
25
0.00 일간 변동폭 0.00
5.60 52주 범위 17.58
market_cap
438.037M
전일 종가
8.27
개장가
-
최근 거래 시간
4
@
8.37
마지막 거래 시간
22:10:44
재정 규모
-
VWAP
-
평균 볼륨(3m)
816,623
발행 주식
52,966,977
배당수익률
-
주가수익률
-4.18
주당순이익(EPS)
-1.98
매출
8.78M
순이익
-104.7M

Stoke Therapeutics Inc 정보

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively... Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.stoketherapeutics.com
본부
Dover, Delaware, USA
설립됨
-
Stoke Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker STOK. The last closing price for Stoke Therapeutics was US$8.27. Over the last year, Stoke Therapeutics shares have traded in a share price range of US$ 5.60 to US$ 17.58.

Stoke Therapeutics currently has 52,966,977 shares in issue. The market capitalisation of Stoke Therapeutics is US$438.04 million. Stoke Therapeutics has a price to earnings ratio (PE ratio) of -4.18.

STOK 최신 뉴스

추가 뉴스

Form 8-K - Current report
Edgar (US Regulatory)
19 2월 2025
STOK (0.24%)

Form 8-K - Current report
Edgar (US Regulatory)
07 1월 2025
STOK (0.24%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
28 12월 2024
STOK (0.24%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-1.03-11.07526881729.39.338.139589658.48615111CS
4-2.39-22.420262664210.6612.988.1387153710.32361549CS
12-4.26-33.998403830812.5314.3858.1381662310.57927026CS
26-5.86-41.472045293714.1316.158.1367396111.78375374CS
521.5823.61733931246.6917.585.683916312.31897198CS
156-11.15-57.415036045319.4226.63.3547052211.57604175CS
260-16.69-66.866987179524.9671.583.3535069315.53318914CS

STOK - Frequently Asked Questions (FAQ)

What is the current Stoke Therapeutics share price?
The current share price of Stoke Therapeutics is US$ 8.27
How many Stoke Therapeutics shares are in issue?
Stoke Therapeutics has 52,966,977 shares in issue
What is the market cap of Stoke Therapeutics?
The market capitalisation of Stoke Therapeutics is USD 438.04M
What is the 1 year trading range for Stoke Therapeutics share price?
Stoke Therapeutics has traded in the range of US$ 5.60 to US$ 17.58 during the past year
What is the PE ratio of Stoke Therapeutics?
The price to earnings ratio of Stoke Therapeutics is -4.18
What is the cash to sales ratio of Stoke Therapeutics?
The cash to sales ratio of Stoke Therapeutics is 49.88
What is the reporting currency for Stoke Therapeutics?
Stoke Therapeutics reports financial results in USD
What is the latest annual turnover for Stoke Therapeutics?
The latest annual turnover of Stoke Therapeutics is USD 8.78M
What is the latest annual profit for Stoke Therapeutics?
The latest annual profit of Stoke Therapeutics is USD -104.7M
What is the registered address of Stoke Therapeutics?
The registered address for Stoke Therapeutics is 3500 S DUPONT HWY, KENT, DOVER, DELAWARE, 19901
What is the Stoke Therapeutics website address?
The website address for Stoke Therapeutics is www.stoketherapeutics.com
Which industry sector does Stoke Therapeutics operate in?
Stoke Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
TRIThomson Reuters Corporation
US$ 178.40
(790.66%)
1.83k
ULYUrgent ly Inc
US$ 0.8461
(101.45%)
35.18M
XNETXunlei Ltd
US$ 4.9999
(72.41%)
15.98M
ANNAAleAnna Inc
US$ 11.31
(59.97%)
11
NIXXNixxy Inc
US$ 2.2399
(41.77%)
29.58M
TOIIWOncology Institute Inc
US$ 0.0186
(-54.52%)
2
SPGCSacks Parente Golf Inc
US$ 0.514
(-29.79%)
1.13M
UVSPUnivest Financial Corporation
US$ 21.17
(-29.34%)
6
DMRCDigimarc Corporation
US$ 19.20
(-28.99%)
43.92k
HBNCHorizon Bancorp Inc
US$ 12.30
(-25.59%)
7
ULYUrgent ly Inc
US$ 0.8451
(101.21%)
35.18M
NIXXNixxy Inc
US$ 2.24
(41.77%)
29.58M
QNRXQuoin Pharmaceuticals Ltd
US$ 0.3875
(25.89%)
29.1M
TRNRInteractive Strength Inc
US$ 1.69
(35.20%)
25.62M
VMARVision Marine Technologies Inc
US$ 0.8724
(19.34%)
18M

STOK Discussion

게시물 보기
PonkenPlonken PonkenPlonken 3 월 전
I am so STOKED about this company. They were doing this before they all figured out you need RNA science for gene therapy.
See SRPT ARWR deal! another AAV based gene tx seeking RNAI
👍️0
Monksdream Monksdream 6 월 전
FOLD under $15
👍️0
Zardiw Zardiw 11 월 전
$STOK Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z
👍️0
TimeFades TimeFades 11 월 전
Choppy day shoulda just stuck with my morning short
👍️0
TimeFades TimeFades 11 월 전
Got bullish again and covered
👍️0
TimeFades TimeFades 11 월 전
Short from 12s
👍️0
Invest-in-America Invest-in-America 11 월 전
STOK: "Stoke Therapeutics (NASDAQ:STOK) stock shot up 70% in post-market trading Monday after the company reported positive results from studies for its drug STK-001 in the treatment of children and adolescents with Dravet syndrome, a genetic form of epilepsy. The biotech company said data from two Phase 1/2a studies and two open label extension, or OLE, studies showed “clinically meaningful effects” that included “substantial and durable reductions in convulsive seizure frequency."
https://seekingalpha.com/news/4083468-stoke-stock-soars-post-market-on-epilepsy-drug-data

Dravet Syndrome is an extremely RARE disease in the USA. And the above news does NOT specify nor suggest that STOK's (potential) treatment for Dravet Syndrome will or might have any applications for treatment of EPILEPSY at all. (Be very CAREFUL about news like the above.)
👍️0

최근 히스토리

NASDAQ
STOK
Stoke Therapeutics
BIT
F35187
Vontobel Financial Produ...
BIT
F15542
Vontobel Financial Produ...
BIT
P1HI13
BNP Paribas Issuance BV
BIT
SDIV
Global X Superdividend U...
BIT
FDE
Frendy Energy
UNSW3
ZENXETH
Zenith
BIT
S30581
Societe Generale Effekten
BIT
I07282
INTESA SANPAOLO
BIT
AEMD
Amundi Ind Msci Emerging...
BIT
VUSA
Vanguard S&P 500 UCITS ETF
BIT
UB51MK
Unicredit Bank
BIT
GS0172
Goldman Sachs
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지